BioAgilytix Labs LLC, a contract research organization supporting pharmaceutical and biotech partners in all phases of drug development, has appointed Dr. Linda Robbie as chief operating officer, effective August 9, 2022.
Cinven has agreed to acquire a majority stake in BioAgilytix, a global ncontract research organisation with a focus on large molecule nbioanalytical testi
DURHAM, N.C., Oct. 4, 2021 /PRNewswire/ -- BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, announced today that it signed a formal, worldwide partnership agreement with global contract research organization Clinical Trial and Consulting Services (CTI). The partnership enables both BioAgilytix and CTI to provide their customers with mutually complementary services, further streamlining the customer experience and expediting drug development.
BioAgilytix Labs, LLC, a global CRO, signed a formal, worldwide partnership agreement with Clinical Trial and Consulting Services (CTI), enabling both BioAgilytix and CTI to provide their customers with mutually complementary services as part of an effort to streamline the customer experience and expediting drug development.
BioAgilytix Labs, LLC, a global CRO, signed a formal, worldwide partnership agreement with Clinical Trial and Consulting Services (CTI), enabling both BioAgilytix and CTI to provide their customers with mutually complementary services as part of an effort to streamline the customer experience and expediting drug development.
DURHAM, N.C., Aug. 18, 2021 /PRNewswire/ -- BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to acquire MicroConstants, adding it to its family of companies.
BioAgilytix Labs, LLC, a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, has signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia.
BioAgilytix, a leading bioanalytical laboratory specializing in large molecule bioanalysis, welcomes Amanda L. Hays, Ph.D. to its team as Scientific Officer. Dr. Hays will provide consultative support to our clients and scientific advisory services to the BioAgilytix team in the development and implementation of strategies for bioanalytical assay development and regulated assay validation.